NasdaqGM - Nasdaq Real Time Price USD

Nurix Therapeutics, Inc. (NRIX)

9.30

-0.35

(-3.58%)

At close: May 7 at 4:00:00 PM EDT

9.30

0.00

(0.00%)

After hours: May 7 at 4:49:35 PM EDT

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for NRIX

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Therapeutics First Quarter 2025 Earnings: Beats Expectations

Nurix Therapeutics First Quarter 2025 Earnings: Beats Expectations

Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates

Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program

NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program

Nurix Therapeutics, Inc. (NRIX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Nurix Therapeutics, Inc. (NRIX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Nurix Therapeutics Signs Exclusive Licensing Deal With Sanofi for Autoimmune Disease Program

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

KYMR Kymera Therapeutics, Inc.

29.11

+1.89%

ITOS iTeos Therapeutics, Inc.

6.44

-2.72%

ORIC ORIC Pharmaceuticals, Inc.

4.7000

-6.75%

ALXO ALX Oncology Holdings Inc.

0.4841

-3.89%

XNCR Xencor, Inc.

7.99

-5.61%

KURA Kura Oncology, Inc.

5.65

-2.50%

CCCC C4 Therapeutics, Inc.

1.5000

+6.38%

RLAY Relay Therapeutics, Inc.

2.9500

-6.35%

NUVL Nuvalent, Inc.

66.72

-2.16%

IDYA IDEAYA Biosciences, Inc.

17.83

+0.45%